Robert Goldman

7.0k total citations · 2 hit papers
100 papers, 5.4k citations indexed

About

Robert Goldman is a scholar working on Psychiatry and Mental health, Clinical Psychology and Cognitive Neuroscience. According to data from OpenAlex, Robert Goldman has authored 100 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Psychiatry and Mental health, 22 papers in Clinical Psychology and 22 papers in Cognitive Neuroscience. Recurrent topics in Robert Goldman's work include Schizophrenia research and treatment (46 papers), Attention Deficit Hyperactivity Disorder (23 papers) and Bipolar Disorder and Treatment (21 papers). Robert Goldman is often cited by papers focused on Schizophrenia research and treatment (46 papers), Attention Deficit Hyperactivity Disorder (23 papers) and Bipolar Disorder and Treatment (21 papers). Robert Goldman collaborates with scholars based in United States, Germany and Australia. Robert Goldman's co-authors include Robert M. Bilder, Jeffrey A. Lieberman, Delbert G. Robinson, Miranda Chakos, Brian Sheitman, Margaret G. Woerner, Stephen Geisler, David Mayerhoff, Jose Ma. J. Alvir and A. Koreen and has published in prestigious journals such as New England Journal of Medicine, American Journal of Psychiatry and Stroke.

In The Last Decade

Robert Goldman

99 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Predictors of Relapse Following Response From a First Episode of Schizophrenia or Schizoaffective Disorder

1999 1.0k citations Delbert G. Robinson, Margaret G. Woerner et al. Archives of General Psychiatry profile →
A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia

2020 204 citations Kenneth S. Koblan, Justine Kent et al. profile →

Peers

Countries citing papers authored by Robert Goldman

Since Specialization

Citations

This map shows the geographic impact of Robert Goldman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Goldman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Goldman more than expected).

Fields of papers citing papers by Robert Goldman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Goldman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Goldman. The network helps show where Robert Goldman may publish in the future.

Co-authorship network of co-authors of Robert Goldman

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Goldman. A scholar is included among the top collaborators of Robert Goldman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Goldman. Robert Goldman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term safety and effectiveness of lurasidone in adolescents and young adults with schizophrenia: pooled post hoc analyses of two 12-month extension studies 2024 ·Annals of General Psychiatry ·(unknown), Michael Tocco, Yongcai Mao, Robert Goldman	1
2	Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia 2022 ·European Psychiatry ·Christoph U. Correll, Michael Tocco, Jay Hsu, Robert Goldman, (unknown)	8
3	Tolerability, Safety, and Effectiveness of Two Years of Treatment with Lurasidone in Children and Adolescents with Bipolar Depression 2021 ·Journal of Child and Adolescent Psychopharmacology ·Melissa P. DelBello, Michael Tocco, (unknown), Ling Deng, Robert Goldman	7
4	Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study 2021 ·Schizophrenia ·Christoph U. Correll, Kenneth S. Koblan, Seth C. Hopkins, Yan Li, (unknown), Robert Goldman, Antony Loebel	61
5	138 Efficacy and Safety of SEP-363856, a Novel Psychotropic Agent with a Non-D2 Mechanism of Action, in the Treatment of Schizophrenia 2020 ·CNS Spectrums ·Kenneth S. Koblan, Seth C. Hopkins, Justine Kent, Hailong Cheng, Robert Goldman, Antony Loebel	6
6	Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, fixed-dose clinical trial 2020 ·CNS Spectrums ·Carlos M. Grilo, Susan L. McElroy, James I. Hudson, Joyce Tsai, Bradford Navia, Robert Goldman, Ling Deng, Justine Kent, Antony Loebel	20
7	Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial 2019 ·Journal of Child and Adolescent Psychopharmacology ·Robert L. Findling, Lenard A. Adler, Thomas Spencer, Robert Goldman, Seth C. Hopkins, Kenneth S. Koblan, Justine Kent, Jay Hsu, Antony Loebel	29
8	Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study 2017 ·Journal of Child and Adolescent Psychopharmacology ·Robert Goldman, Antony Loebel, Josephine Cucchiaro, Ling Deng, Robert L. Findling	40
9	Identifying Amnestic Mild Cognitive Impairment in Primary Care 2011 ·Clinical Drug Investigation ·Rachelle S. Doody, Steven H. Ferris, Stephen Salloway, Thomas Meuser, Anita Murthy, Chunming Li, Robert Goldman	7
10	Circumstances Under Which Practice Does Not Make Perfect: A Review of the Practice Effect Literature in Schizophrenia and Its Relevance to Clinical Treatment Studies 2010 ·Neuropsychopharmacology ·Terry E. Goldberg, Richard S.E. Keefe, Robert Goldman, Delbert G. Robinson, Philip D. Harvey	90
11	Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia 2008 ·Schizophrenia Research ·Terry E. Goldberg, Katherine E. Burdick, Joanne McCormack, Barbara Napolitano, (unknown), Serge Sevy, Robert Goldman, Todd Lencz, Anil K. Malhotra, John M. Kane, Delbert G. Robinson	47
12	Cognitive Improvement After Treatment With Second-Generation Antipsychotic Medications in First-Episode Schizophrenia 2007 ·Archives of General Psychiatry ·Terry E. Goldberg, Robert Goldman, Katherine E. Burdick, Anil K. Malhotra, Todd Lencz, (unknown), Margaret G. Woerner, Nina R. Schooler, John M. Kane, Delbert G. Robinson	321
13	First-episode schizophrenia: characterization and clinical correlates 2007 ·Robert M. Bilder, Robert Goldman, Delbert G. Robinson, G. Reiter, (unknown), John A. Bates, Elizabeth Pappadopulos, (unknown), Margaret G. Woerner, Stephen Geisler, John M. Kane	3
14	Lack of Normal Association Between Cerebellar Volume and Neuropsychological Functions in First-Episode Schizophrenia 2003 ·American Journal of Psychiatry ·Philip R. Szeszko, Faith M. Gunning‐Dixon, Robert Goldman, John A. Bates, Manzar Ashtari, Peter J. Snyder, Jeffrey A. Lieberman, Robert M. Bilder	33
15	IQ scores of treatment-resistant schizophrenia patients before and after the onset of the illness 2000 ·Schizophrenia Research ·Brian Sheitman, Michael G. Murray, Jennifer Snyder, Susan G. Silva, Robert Goldman, Miranda Chakos, Jan Volavka, Jeffrey A. Lieberman	24
16	Reduced anterior cingulate gyrus volume correlates with executive dysfunction in men with first-episode schizophrenia 2000 ·Schizophrenia Research ·Philip R. Szeszko, Robert M. Bilder, Todd Lencz, Manzar Ashtari, Robert Goldman, G. Reiter, Houwei Wu, Jeffrey A. Lieberman	85
17	Auditory Sensory Dysfunction in Schizophrenia 2000 ·Archives of General Psychiatry ·Esther Rabinowicz, Gail Silipo, Robert Goldman, Daniel C. Javitt	138
18	Predictors of Relapse Following Response From a First Episode of Schizophrenia or Schizoaffective Disorder breakdown → 1999 ·Archives of General Psychiatry ·Delbert G. Robinson, Margaret G. Woerner, Jose Ma. J. Alvir, Robert M. Bilder, Robert Goldman, Stephen Geisler, A. Koreen, Brian Sheitman, Miranda Chakos, David Mayerhoff, Jeffrey A. Lieberman	1014
19	Ventricular enlargement, neuropsychological status, and premorbid function in schizophrenia 1994 ·Biological Psychiatry ·J.R. DeQuardo, Rajiv Tandon, Robert Goldman, James H. Meador‐Woodruff, (unknown), James A. Brunberg, (unknown)	39
20	Analysis of Executive Functioning in Schizophrenics Using the Wisconsin Card Sorting Test 1991 ·The Journal of Nervous and Mental Disease ·Robert Goldman, Bradley N. Axelrod, Rajiv Tandon, Stanley Berent	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact